The immune system and the inflammatory response

Textbook of Pediatric Rheumatology

Volumn , Issue , 2005, Pages 19-63

  Gattorno, Marco ^a   Martini, Alberto ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79953829123     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-0246-8.50009-7     Document Type: Chapter

References (246)

1. Abbas AK, Lichtman AH Cellular and Molecular Immunology 2003, WB Saunders, Philadelphia. 5th ed.
2. Janeway CA, Travers P, Walport M, Shlomchik M Immunobiology 2001, Garland Publishing, New York.
3. Fundamental Immunology 1998, Raven Press, New York. 4th ed. W.E. Paul (Ed.).
4. Medzhitov R, Janeway C Innate immunity. N Engl J Med 2000, 343:338-344.
5. Medzhitov R Toll-like receptors and innate immunity. Nat Rev Immunology 2001, 1:135-145.
6. Takeda K, Kaisho T, Akira S Toll-like receptors. Ann Rev Immunol 2003, 21:335-376.
7. Pasare C, Medzhitov R Toll-like receptors: balancing host resistance with immune tolerance. Curr Opin Immunol 2003, 15:677-682.
8. Gordon S Alternative activation of macrophages. Nat Rev Immunol 2003, 3:23-35.
9. Mosser DM The many faces of macrophage activation. J Leukoc Biol 2003, 73:209-212.
10. Banchereau J, Steinman RM Dendritic cells and the control of immunity. Nature 1998, 392:245-252.
11. Shortman K, Liu YJ Mouse and human dendritic cell subtypes. Nat Rev Immunol 2002, 2:151-161.
12. Sallusto F, Lanzavecchia A The instructive role of dendritic cells on T cell responses. Arthritis Res (Suppl 3) 2002, S127-S132.
13. Guermonprez P, Valladeau J, Zitvogel L, et al. Antigen presentation and T cell stimulation by dendritic cells. Ann Rev Immunol 2002, 20:621-667.
14. Kadowaki N, Ho S, Antonenko S, et al. Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J Exp Med 2001, 194:863-869.
15. Blanco P, Palucka AK, Gill M, et al. Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science 2001, 294:1540-1543.
16. Ronnblom L, Alm GV A pivotal role for the natural interferon alpha-producing cells (plasmacytoid dendritic cells) in the pathogenesis of lupus. J Exp Med 2001, 194:59-63.
17. Mahnke K, Knop J, Enk AH Induction of tolerogenic DCs: "You are what you eat.". Trends Immunol 2003, 24:646-651.
18. Colucci F, Caligiuri MA, Di Santo JP What does it take to make a natural killer?. Nat Rev Immunol 2003, 3:413-425.
19. Moretta A, Bottino C, Vitale M, et al. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol 2001, 19:197-223.
20. Biassoni R, Cantoni C, Marras D, et al. Human natural killer cell receptors: insights into their molecular function and structure. J Cell Mol Med 2003, 7:376-387.
21. Buckley CD, Pilling D, Lord JM, et al. Fibroblasts regulate the switch from acute resolving to chronic persistent inflammation. Trends Immunol 2001, 22:199-204.
22. Molina H Complement and immunity. Rheum Dis Clin North Am 2004, 30:1-18.
23. Taylor PR, Carugati A, Fadok VA, et al. A hierarchical role for classical pathway complement proteins in the clearance of apoptotic cells in vivo. J Exp Med 2000, 192:359-366.
24. Manderson AP, Botto M, Walport MJ The role of complement in the development of systemic lupus erythematosus. Annu Rev Immunol 2004, 22:431-456.
25. Kemper C, Chan AC, Green JM, et al. Activation of human CD4+ cells with CD3 and CD46 induces a T-regulatory cell 1 phenotype. Nature 2003, 421:388-392.
26. Sohn JH, Bora PS, Suk HJ, et al. Tolerance is dependent on complement C3 fragment iC3b binding to antigen-presenting cells. Nat Med 2003, 9:206-212.
27. Kilpatrick DC Mannan-binding lectin and its role in innate immunity. Transfus Med 2002, 12:335-352.
28. Mantovani A, Garlanda C, Bottazzi B Pentraxin 3, a non-redundant soluble pattern recognition receptor involved in innate immunity. Vaccine 2003, 21(Suppl 2):S43-S47.
29. Ganz T Defensins: antimicrobial peptides of innate immunity. Nat Rev Immunol 2003, 3:710-720.
30. Frazer DT, Capra JD Immunoglobulins: structure and function. Fundamental Immunology 1998, Raven Press, New York. 4th ed. W.E. Paul (Ed.).
31. Fearon DT, Carroll MC Regulation of B lymphocyte responses to foreign and self-antigens by the CD19/CD21 complex. Annu Rev Immunol 2000, 18:393-422.
32. Max EE Immunogobulins: molecular genetics. Fundamental Immunology 1998, Raven Press, New York. 4th ed. W.E. Paul (Ed.).
33. Wagner SD, Neuberger MS Somatic hypermutation of immunoglobulin genes. Annu Rev Immunol 1996, 14:441-457.
34. Hardy RR, Hayakawa K B cell development pathways. Annu Rev Immunol 2001, 19:595-621.
35. Nemazee D Receptor selection in B and T lymphocytes. Annu Rev Immunol 2000, 18:19-51.
36. Murakami M, Honjo T Involvement of B-1 cells in mucosal immunity and autoimmunity. Immunol Today 1995, 16:534-539.
37. Raman C CD5, an important regulator of lymphocyte selection and immune tolerance. Immunol Res 2002, 26:255-264.
38. Ashwell JD, Klausner RD Genetic and mutational analysis of the T-cell antigen receptor. Annu Rev Immunol 1990, 8:139-167.
39. Muljo SA, Schlissel MS Pre-B and pre-T-cell receptors: conservation of strategies in regulating early lymphocyte development. Immunol Rev 2000, 175:80-93.
40. Zinkemagel RM, Doherty PC Restriction of in vivo T-cell mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system. Nature 1974, 248:701-702.
41. Li H, Lebedeva MI, Llera AS, et al. Structure of the Vd domain of a human g:d T-cell antigen receptor. Nature 1998, 391:502-506.
42. Hayday A γδ cells: a right time and a right place for a conserved third way of protection. Annu Rev Immunol 2000, 18:975-1026.
43. Hayday A, Tigelaar R Immunoregulation in the tissues by gammadelta T cells. Nat Rev Immunol 2003, 3:233-242.
44. Malissen B, Malissen M Functions of TCR and preTCR subunits: lessons from gene ablation. Curr Opin Immunol 1996, 8:383-393.
45. Peterson EJ, Koretzky GA Signal transduction in T lymphocytes. Clin Exp Rheumatol 1999, 17:107-114.
46. Zamoyska R CD4 and CD8: modulators of T cell receptor recognition of antigen and of immune response?. Curr Opin Immunol 1998, 10:82-87.
47. Rammensee HG Chemistry of peptides associated with MHC class I and II molecules. Curr Opin Immunol 1995, 7:85-96.
48. Germain RN MHC-dependent antigen processing and peptide presentation: providing ligands for T lymphocyte activation. Cell 1994, 76:287-299.
49. York IA, Rock KL Antigen processing and presentation by the class I major histocompatibility complex. Annu Rev Immunol 1996, 14:369-396.
50. Franco A, Ferrari C, Sette A, Chisari FV Viral mutations, TCR antagonism and escape from the immune system. Curr Opin Immunol 1995, 7:524-531.
51. Srivastava P Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses. Annu Rev Immunol 2002, 20:395-425.
52. Anderson G, Moore NC, Owen JJ, et al. Cellular interactions in thymic development. Annu Rev Immunol 1996, 14:73-99.
53. Shortman K, Wu L Early T lymphocyte progenitors. Annu Rev Immunol 1996, 14:29-47.
54. Starr TK, Jameson SC, Hogquist KA Positive and negative selection of T cells. Annu Rev Immunol 2003, 21:139-176.
55. Ashton-Rickardt PG, Bandeira A, Delaney JR, et al. Evidence for a differential avidity model of T-cell selection in the thymus. Cell 1994, 74:651-663.
56. Lenschow DJ, Walunas TL, Bluestone JA CD28/B7 system of T cell costimulation. Annu Rev Immunol 1996, 14:233-258.
57. Rudd CE Upstream-downstream: CD28 cosignaling pathways and T cell function. Immunity 1996, 4:527-534.
58. Dong C, Nurieva RI, Prasad DV Immune regulation by novel costimulatory molecules. Immunol Res 2003, 28:39-48.
59. Banchereau J, Bazan F, Blanchard D, et al. The CD40 antigen and its ligand. Annu Rev Immunol 1994, 12:881-922.
60. Lanzavecchia A License to kill. Nature 1998, 393:413-414.
61. Medzhitov R, Janeway CA Innate immunity: the virtues of a nonclonal system of recognition. Cell 1997, 91:295-298.
62. Banchereau J, Briere F, Caux C, et al. Immunobiology of dendritic cells. Annu Rev Immunol 2000, 18:767-811.
63. Lanzavecchia A Receptor-mediated antigen uptake and its effect on antigen presentation to class II-restricted T lymphocytes. Annu Rev Immunol 1990, 8:773-793.
64. Kersh GJ, Allen PM Essential flexibility in the T-cell recognition of antigen. Nature 1996, 380:495-498.
65. Malissen B Translating affinity into response. Science 1998, 281:528-529.
66. Nicholson LB, Greer JM, Sobel RA, et al. An altered peptide ligand mediates immune deviation and prevents autoimmune encephalomyelitis. Immunity 1995, 3:397-405.
67. Llewelyn M, Cohen J Superantigens: microbial agents that corrupt immunity. Lancet Infect Dis 2002, 2:156-162.
68. Abbas AK, Murphy KM, Sher A Functional diversity of helper T lymphocytes. Nature 1996, 383:787-793.
69. Romagnani S The Th1/Th2 paradigm. Immunol Today 1997, 18:263-266.
70. Bottomly K T cells and dendritic cells get intimate. Science 1999, 283:1124-1125.
71. Murphy KM, Ouyang W, Farrar JD, et al. Signaling and transcription in T helper development. Annu Rev Immunol 2000, 18:451-494.
72. Szabo SJ, Kim ST, Costa GL, et al. A novel transcription factor, T-beta, directs Th1 lineage commitment. Cell 2000, 17:655-669.
73. Das J, Chen CH, Yang L, et al. A critical role for NF-kappa B in GATA3 expression and TH2 differentiation in allergic airway inflammation. Nat Immunol 2001, 2:45-50.
74. Grogan JL, Locksley RM T helper cell differentiation: on again, off again. Curr Opin Immunol 2002, 14:366-372.
75. Messi M, Giacchetto I, Nagata K, et al. Memory and flexibility of cytokine gene expression as separable properties of human T(H)1 and T(H)2 lymphocytes. Nat Immunol 2003, 4:78-86.
76. Sallusto F, Mackay CR, Lanzavecchia A The role of chemokine receptors in primary, effector, and memory immune responses. Annu Rev Immunol 2000, 18:593-620.
77. Russell JH, Ley TJ Lymphocyte-mediated cytotoxicity. Annu Rev Immunol 2002, 20:323-370.
78. Fagarasan S, Honjo T T independent immune response: new aspects of B cell biology. Science 2000, 290:89-92.
79. De Franco AL B-cell activation. Immunol Rev 2000, 176:5-9.
80. Stavnezer J Immunoglobulin class switching. Curr Opin Immunol 1996, 8:199-205.
81. MacLennan ICM Germinal centers. Annu Rev Immunol 1994, 12:117-139.
82. Mackay F, Browning JL BAFF a fundamental survival factor for B cells. Nat Rev Immunol 2002, 2:465-475.
83. O'Connor BP, Gleeson MW, Noelle RJ, Erickson LD The rise and fall of long-lived humoral immunity: terminal differentiation of plasma cells in health and disease. Immunol Rev 2003, 194:61-76.
84. Traggiai E, Puzone R, Lanzavecchia A Antigen dependent and independent mechanisms that sustain serum antibody levels. Vaccine 2003, 21(Suppl 2):S35-S37.
85. Liszewski MK, Farries TC, Lublin DM, et al. Control of the complement system. Adv Immunol 1996, 61:201-283.
86. Ravetch JV, Kinet J Fc receptors. Annu Rev Immunol 1993, 9:457-492.
87. Ahmed R, Gray D Immunological memory and protective immunity: understanding their relation. Science 1996, 272:54-60.
88. Ahmed R Tickling memory T cells. Science 1996, 272:1904.
89. Dutton RW, Bradley LM, Swain SL T cell memory. Annu Rev Immunol 1998, 16:201-223.
90. Slifka MK, Antia R, Whitmire JK, Ahmed R Humoral immunity due to long-lived plasma cells. Immunity 1998, 8:363-372.
91. Maruyama M, Lam KP, Rajewsky K Memory B-cell persistence is independent of persisting immunizing antigen. Nature 2000, 407:636-642.
92. Bernasconi NL, Traggiai E, Lanzavecchia A Maintenance of serological memory by polyclonal activation of human memory B cells. Science 2002, 298:2199-2202.
93. Sallusto F, Lenig D, Forster R, et al. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999, 401:708-712.
94. Sallusto F, Lanzavecchia A Exploring pathways for memory T cell generation. J Clin Invest 2001, 108:805-806.
95. Van Parijs L, Abbas AK Homeostasis and self-tolerance in the immune system: turning lymphocytes off. Science 1998, 280:243-248.
96. Tivol EA, Borriello F, Schweitzer AN, et al. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995, 3:541-547.
97. Waterhouse P, Penninger JM, Timms E, et al. Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Science 1995, 270:985-988.
98. Mason D, Powrie F Control of immune pathology by regulatory T cells. Curr Opin Immunol 1998, 10:649-655.
99. Sadlack B, Merz H, Schorle H, et al. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 1993, 75:253-261.
100. Willerford DM, Chen J, Ferry JA, et al. Interleukin-2 receptor alpha chain regulates the size and content of the peripheral lymphoid compartment. Immunity 1995, 3:521-530.
101. Suzuki H, Kundig TM, Furlonger C, et al. Deregulated T cell activation and autoimmunity in mice lacking interleukin-2. Science 1995, 268:1472-1476.
102. Abbas AK The control of T cell activation vs. tolerance. Autoimmun Rev 2003, 2:115-118.
103. Danial NN, Korsmeyer SJ Cell death: critical control points. Cell 2004, 116:205-219.
104. Ashkenazi A, Dixit VM Death receptors: signaling and modulation. Science 1998, 281:1305-1308.
105. Green DR, Droin N, Pinkoski M Activation-induced cell death in T cells. Immunol Rev 2003, 193:70-81.
106. Thornberry NA, Lazebnik Y Caspases: enemies within. Science 1998, 281:1312-1316.
107. Nagata S, Suda T Fas and Fas ligand: lpr and gld mutations. Immunol Today 1995, 16:39-43.
108. Drappa J, Vaishnaw AK, Sullivan KE, et al. Fas gene mutations in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity. N Engl J Med 1996, 335:1643-1649.
109. Van Parijs L, Peterson DA, Abbas AK The Fas/Fas ligand pathways and bcl-2 regulate T cell responses to model self and foreign antigens. Immunity 1998, 8:265-274.
110. Kamradt T, Mitchison NA Tolerance and autoimmunity. N Engl J Med 2001, 344:655-664.
111. Goodnow CC Balancing immunity and tolerance: deleting and tuning lymphocyte repertoires. Proc Natl Acad Sci U S A 1996, 93:2264-2271.
112. Mondino A, Khoruts A, Jenkins MK The anatomy of T-cell activation and tolerance. Proc Natl Acad Sci U S A 1996, 93:2245-2252.
113. Sakaguchi S Regulatory T cells: key controllers of immunologic self-tolerance. Cell 2000, 101:455-458.
114. Hanahan D Peripheral-antigen-expressing cells in thymic medulla: factors in self-tolerance and autoimmunity. Curr Opin Immunol 1998, 10:656-662.
115. Anderson MS, Venanzi ES, Klein L, et al. Projection of an immunological self shadow within the thymus by the aire protein. Science 2002, 298:1395-1401.
116. Peterson P, Nagamine K, Scott A, et al. APECED: a monogenic autoimmune disease providing new clues to self-tolerance. Immunol Today 1998, 19:384-386.
117. Mathis D, Benoist C Back to central tolerance. Immunity 2004, 20:509-516.
118. Wu J, Wilson J, He J, et al. Fas ligand mutation in a patient with systemic lupus erythematosus and lymphoproliferative disease. J Clin Invest 1996, 98:1107-1113.
119. Wang J, Zheng L, Lobito A, et al. Inherited human caspase 10 mutations underlie defective lymphocyte and dendritic cell apoptosis in autoimmune lymphoproliferative syndrome type II. Cell 1999, 98:47-58.
120. Savill J, Dransfield I, Gregory C, Haslett C A blast from the past: clearance of apoptotic cells regulates immune responses. Nat Rev Immunol 2002, 2:965-975.
121. Shevach EM CD4+ CD25+ suppressor T cells: more questions than answers. Nat Rev Immunol 2002, 2:389-400.
122. Hori S, Takahashi T, Sakaguchi S Control of autoimmunity by naturally arising regulatory CD4+ T cells. Adv Immunol 2003, 81:331-371.
123. Groux H, O'Garra A, Bigler M, et al. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997, 389:737-742.
124. Levings MK, Roncarolo MG T-regulatory 1 cells: a novel subset of CD4 T cells with immunoregulatory properties. J Allergy Clin Immunol 2000, 106:S109-S112.
125. Prud'homme GJ, Piccirillo CA The inhibitory effects of transforming growth factor-beta-1 (TGF-beta1) in autoimmune diseases. J Autoimmun 2000, 14:23-42.
126. Sakaguchi S, Sakaguchi N, Asano M, et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25): breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995, 155:1151-1164.
127. Hori S, Nomura T, Sakaguchi S Control of regulatory T cell development by the transcription factor Foxp3. Science 2003, 299:1057-1061.
128. Wildin RS, Smyk-Pearson S, Filipovich AH Clinical and molecular features of the immunodysregulation, polyendocrinopathy, enteropathy, X linked (IPEX) syndrome. J Med Genet 2002, 39:445-537.
129. Benoist C, Mathis D Autoimmunity: the pathogen connection. Nature 1998, 394:227-228.
130. Griffith TS, Ferguson TA The role of Fas-L induced apoptosis in immune privilege. Immunol Today 1997, 18:240-244.
131. Strobel S, Mowat AM Immune responses to dietary antigens: oral tolerance. Immunol Today 1998, 19:173-181.
132. MacDonald TT The mucosal immune system. Parasite Immunol 2003, 25:235-246.
133. Weiner HL Oral tolerance: immune mechanisms and treatment of autoimmune diseases. Immunol Today 1997, 18:335-343.
134. Mayer L, Shao L Therapeutic potential of oral tolerance. Nat Rev Immunol 2004, 4:407-419.
135. Vyse TJ, Todd JA Genetic analysis of autoimmune disease. Cell 1996, 85:311-318.
136. Winchester R The genetics of autoimmune-mediated rheumatic diseases: clinical and biologic implications. Rheum Dis Clin North Am 2004, 30:213-227.
137. Marrack P, Kappler J, Kotzin BL Autoimmune disease: why and where it occurs. Nat Med 2001, 7:899-905.
138. Sood R, Blake T, Aksentijevich I, et al. Construction of a 1-Mb restriction-mapped cosmid containing the candidate region for the familial Mediterranean fever locus (MEFV) on chromosome 16p 13.3. Genomics 1997, 42:83-95.
139. McDermott MF, Aksentijevich I, Galon J, et al. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell 1999, 97:133-144.
140. Feldmann J, Prieur AM, Quartier P, et al. Chronic infantile neurological cutaneous and articular syndrome is caused by mutations in CIAS1, a gene highly expressed in polymorphonuclear cells and chondrocytes. Am J Hum Genet 2002, 71:198-203.
141. Miceli-Richard C, Lesage S, Rybojad M, et al. CARD15 mutations in Blau syndrome. Nat Genet 2001, 29:19-20.
142. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001, 41:599-603.
143. Kantarci OH, Hebrink DD, Achenbach SJ, et al. CTLA-4 is associated with susceptibility to multiple sclerosis. J Neuroimmunol 2003, 134:133-141.
144. Xia B, Crusius JB, Wu J, et al. CTLA-4 gene polymorphisms in Dutch and Chinese patients with inflammatory bowel disease. Scand J Gastroenterol 2002, 37:1296-1300.
145. Kouki T, Gardine CA, Yanagawa T, et al. Relation of three polymorphisms of the CTLA-4 gene in patients with Graves disease. J Endocrinol Invest 2002, 25:208-213.
146. Rodrigues MR, Nunez-Roldan A, Aguilar F, et al. Association of the CTLA-4 3′ untranslated region polymorphism with the susceptibility to rheumatoid arthritis. Hum Immunol 2002, 63:76-81.
147. Prokunina L, Castillejo-Lopez C, Oberg F, et al. A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans. Nat Genet 2002, 32:666-669.
148. Ridgway WM, Fathman CG The association of MHC with autoimmune diseases: understanding the pathogenesis of autoimmune diabetes. Clin Immunol Immunopathol 1998, 86:3-10.
149. Andersson EC, Svendsen P, Svejgaard A, et al. Rev Immunogenet. A molecule basis for the HLA association in rheumatoid arthritis. Rev Immunogenet 2000, 2:81-87.
150. Botto M, Walport MJ C1q, autoimmunity and apoptosis. Immunobiology 2002, 205:395-406.
151. Salmon JE, Millard S, Schachter LA, et al. Fc gamma RIIA alleles are heritable risk factors for lupus nephritis in African Americans. Clin Invest 1996, 97:1348-1354.
152. Hausmann S, Wucherpfennig W Activation of autoreactive T cells by peptides from human pathogens. Curr Opin Immunol 1997, 9:831-838.
153. Miller SD, McRae BL, Vanderlugt CL, et al. Evolution of the T-cell repertoire during the course of experimental immune-mediated demyelinating disease. Immunol Rev 1995, 144:225-244.
154. Kaufman DL, Clare-Salzler M, Tian J, et al. Spontaneous loss of T cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetes. Nature 1993, 366:69-72.
155. Wekerle H The viral triggering of autoimmune disease. Nature Med 1998, 4:770-771.
156. Holoshitz J, Naparstek Y, Ben-Nun A, et al. Lines of T lymphocytes induce or vaccinate against autoimmune arthritis. Science 1983, 219:56-58.
157. McLaren NK, Atkinson MA Insulin-dependent diabetes mellitus: the hypothesis of molecular mimicry between islet cell antigens and microorganisms. Mol Med Today 1997, 2:76-83.
158. Wucherpfennig KW, Strominger JL Molecular mimicry in T-cell mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein. Cell 1995, 80:695-705.
159. Gross DM, Forsthuber T, Tary-Lehmann M, et al. Identification of LFA-1 as a candidate autoantigen in treatment-resistant Lyme arthritis. Science 1998, 281:703-706.
160. Albani S, Keystone EC, Ollier WER, et al. Positive selection in autoimmunity: abnormal immune responses to a bacterial dnaj antigenic determinant in patients with early rheumatoid arthritis. Nat Med 1995, 1:448-452.
161. Prakken BJ, Samodal R, Le TD, et al. Epitope-specific immunotherapy induces immune deviation of proinflammatory T cells in rheumatoid arthritis. Proc Natl Acad Sci U S A 2004, 23:4228-4233.
162. Horwitz MS, Bradley LM, Harbertson J, et al. Diabetes induced by Coxsackie virus: initiation by bystander damage and not molecular mimicry. Nat Med 1998, 4:781-785.
163. Segal BM, Dwyer BK, Shevach EM An interleukin (IL)-10/IL-12 immunoregulatory circuit controls susceptibility to autoimmune disease. J Exp Med 1998, 187:537-546.
164. Behar SM, Porcelli SA Mechanisms of autoimmune disease induction. Arthritis Rheum 1995, 38:458-476.
165. Robbie-Ryan M, Brown M The role of mast cells in allergy and autoimmunity. Curr Opin Immunol 2002, 1:728-733.
166. Brucato A, Franceschini F, Doria A, et al. Pathogenetic associations of maternal anti-Ro/SSA antibodies. Lupus 2002, 11:650.
167. Wada K, Kazukawa I, Someya T, et al. Maternal hypothyroidism in autoimmune thyroiditis and the prognosis of infants. Endocr J 2000, 47(Suppl):S133-S135.
168. Webert KE, Mittal R, Sigouin C, et al. A retrospective 11-year analysis of obstetric patients with idiopathic thrombocytopenic purpura. Blood 2003, 102:4306-4311.
169. Martin F, Chan AC Pathogenic roles of B cells in human autoimmunity; insights from the clinic. Immunity 2004, 20:517-527.
170. Trendelenburg M, Schifferli JA Cryoglobulins in chronic hepatitis C virus infection. Clin Exp Immunol 2003, 133:153-155.
171. Lassmann H, Ransohoff RM The CD4-Th1 model for multiple sclerosis: a crucial re-appraisal. Trends Immunol 2004, 25:132-137.
172. Roep BO The role of T-cells in the pathogenesis of type 1 diabetes: from cause to cure. Diabetologia 2003, 46:305-321.
173. Romagnani P, Annunziato F, Baccari MC, Parronchi P T cells and cytokines in Crohn's disease. Curr Opin Immunol 1997, 9:793-799.
174. Panayi GS, Lanchbury JS, Kingsley GH The importance of the T cell in initiating and maintaining the chronic synovitis of rheumatoid arthritis. Arthritis Rheum 1992, 35:729-735.
175. Gattorno M, Facchetti P, Ghiotto F, et al. Synovial fluid T cell clones from oligoarticular juvenile arthritis patients display a prevalent Th1/Th0 patterns of cytokine secretion irrespective to immunophenotype. Clin Exp Immunol 1997, 109:4-11.
176. Wedderburn LR, Robinson N, Patel A, et al. Selective recruitment of polarized T cells expressing CCR5 and CXCR3 to the inflamed joints of children with juvenile idiopathic arthritis. Arthritis Rheum 2000, 43:765-774.
177. Firestein GS Evolving concepts of rheumatoid arthritis. Nature 2003, 423:356-361.
178. Takemura S, Braun A, Crowson C, et al. Lymphoid neogenesis in rheumatoid synovitis. J Immunol 2001, 167:1072-1080.
179. Gebhard JR, Perry CM, Harkins S, et al. Coxsackievirus B3-induced myocarditis: perforin exacerbates disease, but plays no detectable role in virus clearance. Am J Pathol 1998, 153:417-428.
180. Alon R, Feigelson S From rolling to arrest on blood vessels: leukocyte tap dancing on endothelial integrin ligands and chemokines at sub-second contacts. Semin Immunol 2002, 14:93-104.
181. Muller WA Leukocyte-endothelial-cell interactions in leukocyte transmigration and the inflammatory response. Trends Immunol 2003, 24:327-334.
182. Frenette PS, Wagner DD Adhesion molecules: part 1. N Engl J Med 1996, 334:1526-1529.
183. Patel KD, Cuvelier SL, Wiehler S Selectins: critical mediators of leukocyte recruitment. Semin Immunol 2002, 14:73-81.
184. Weber C Novel mechanistic concepts for the control of leukocyte transmigration: specialization of integrins, chemokines, and junctional molecules. Mol Med 2003, 81:4-19.
185. Pribila JT, Quale AC, Mueller KL, Shimizu Y Integrins and T cell-mediated immunity. Ann Rev Immunol 2004, 22:157-180.
186. Alon R, Kassner PD, Carr MW, et al. The integrin VLA-4 supports tethering and rolling in flow on VCAM-1. J Cell Biol 1995, 128:1243-1253.
187. von Andrian UH, Engelhardt B Alpha4 integrins as therapeutic targets in autoimmune disease. N Engl J Med 2003, 348:68-72.
188. Baggiolini M Chemokines in pathology and medicine. J Intern Med 2001, 250:91-104.
189. Campbell DJ, Kim CH, Butcher EC Chemokines in the systemic organization of immunity. Immunol Rev 2003, 195:58-71.
190. Gunn MD, Kyuwa S, Tam C, et al. Mice lacking expression of secondary lymphoid organ chemokine have defects in lymphocyte homing and dendritic cell localization. J Exp Med 1999, 189:451-460.
191. Fais S, Malorni W Leukocyte uropod formation and membrane/cytoskeleton linkage in immune interactions. J Leukoc Biol 2003, 73:556-563.
192. Gerard C, Rollins BJ Chemokines and disease. Nat Immunol 2001, 2:108-115.
193. Lloyd CM, Delaney T, Nguyen T, et al. CC chemokine receptor (CCR)3/eotaxin is followed by CCR4/monocyte-derived chemokine in mediating pulmonary T helper lymphocyte type 2 recruitment after serial antigen challenge in vivo. J Exp Med 2000, 191:265-274.
194. Proudfoot AE Chemokine receptors: multifaceted thěrapeutic targets. Nat Rev Immunol 2002, 2:106-115.
195. Abbas AK, Lichtman AH Cytokines. Cellular and Molecular Immunology 2003, 243-274. WB Saunders, Philadelphia. 5th ed. A.K. Abbas, A.H. Lichtman (Eds.).
196. Feldmann M, Maini RN Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?. Annu Rev Immunol 2001, 19:163-196.
197. O'Shea JJ, Ma A, Lipsky P Cytokines and autoimmunity. Nat Rev Immunol 2002, 2:37-45.
198. Beutler BA, Milsark IW, Cerami A Cachectin/tumor necrosis factor: production, distribution, and metabolic fate in vivo. J Immunol 1985, 135:3972-3977.
199. Dempsey PW, Doyle SE, He JQ, Cheng G The signaling adaptors and pathways activated by TNF superfamily. Cytokine Growth Factor Rev 2003, 14:193-209.
200. Lay JD, Tsao CJ, Chen JY, et al. Upregulation of tumor necrosis factor-alpha gene by Epstein-Barr virus and activation of macrophages in Epstein-Barr virus-infected T cells in the pathogenesis of hemophagocytic syndrome. J Clin Invest 1997, 100:1969-1979.
201. Dinarello CA Biologic basis for interleukin-1 in disease. Blood 1996, 87:2095-2147.
202. Greenfeder SA, Nunes P, Kwee L, et al. Molecular cloning and characterization of a second subunit of the interleukin 1 receptor complex. J Biol Chem 1995, 270:13757-13765.
203. Mantovani A, Locati M, Vecchi A, et al. Decoy receptors: a strategy to regulate inflammatory cytokines and chemokines. Trends Immunol 2001, 22:328-336.
204. Dayer JM Evidence for the biological modulation of IL-1 activity: the role of IL-1Ra. Clin Exp Rheumatol 2002, 20(Suppl 27):S14-S20.
205. Horai R, Saijo S, Tanioka H, et al. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J Exp Med 2000, 191:313-320.
206. Dinarello CA The role of the interleukin-1-receptor antagonist in blocking inflammation mediated by interleukin-1. N Engl J Med 2000, 343:732-734.
207. Hirano T, Yasukawa K, Harada H, et al. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature 1986, 324:73-76.
208. Ishihara K, Hirano T IL-6 in autoimmune disease and chronic inflammatory proliferative disease. Cytokine Growth Factor Rev 2002, 13:357-368.
209. Taga T, Kishimoto T Gp130 and the interleukin-6 family of cytokines. Annu Rev Immunol 1997, 15:797-819.
210. Muller-Newen G The cytokine receptor gp130: faithfully promiscuous. Sci STKE 2003, 201:PE40.
211. De Benedetti F, Massa M, Pignatti P, et al. Serum soluble interleukin 6 (IL-6) receptor and IL-6/soluble IL-6 receptor complex in systemic juvenile rheumatoid arthritis. J Clin Invest 1994, 93:2114-2119.
212. De Benedetti F, Alonzi T, Moretta A, et al. Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-I: a model for stunted growth in children with chronic inflammation. J Clin Invest 1997, 99:643-650.
213. De Benedetti F, Martini A Is systemic juvenile rheumatoid arthritis an interleukin 6 mediated disease?. J Rheumatol 1998, 25:203-207.
214. Cazzola M, Ponchio L, De Benedetti F, et al. Defective iron supply to ery-thropoiesis and adequate endogenous erythropoietin production in the anemia associated with systemic-onset juvenile chronic arthritis. Blood 1996, 87:4824-4830.
215. Yokota S Interleukin 6 as a therapeutic target in systemic-onset juvenile idiopathic arthritis. Curr Opin Rheumatol 2003, 15:581-586.
216. Andersson U, Wang H, Palmblad K, et al. High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med 2000, 192:565-570.
217. Ulloa L, Batliwalla FM, Andersson U, et al. High mobility group box chromosomal protein 1 as a nuclear protein, cytokine, and potential therapeutic target in arthritis. Arthritis Rheum 2003, 48:876-881.
218. Trinchieri G Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003, 3:133-146.
219. Dinarello CA, Fantuzzi G Interleukin-18 and host defense against infection. J Infect Dis 2003, 187(Suppl 2):S370-S384.
220. Lankford CS, Frucht DM A unique role for IL-23 in promoting cellular immunity. Leukoc Biol 2003, 73:49-56.
221. Liew FY The role of innate cytokines in inflammatory response. Immunol Lett 2003, 85:131-134.
222. Koch AE Angiogenesis. Arthritis Rheum 1998, 41:951-962.
223. Szekanecz Z, Koch AE Vascular endothelium and immune responses: implications for inflammation and angiogenesis. Rheum Dis Clin North Am 2004, 30:97-114.
224. Berse B, Hunt JA, Diegel RJ, et al. Hypoxia augments cytokine (transforming growth factor-beta [TGF-βl and IL-1)-induced vascular endothelial growth factor secretion by human synovial fibroblasts. Clin Exp Immunol 1999, 115:176-182.
225. Miotla J, Macjewicz R, Kendrew J, et al. Treatment with soluble VEGF receptor reduces disease severity in murine collagen-induced arthritis. Lab Invest 2000, 80:1195-1205.
226. Turini ME, DuBois RN Cyclooxygenase-2: a therapeutic target. Annu Rev Med 2002, 53:35-57.
227. Samuelsson B, Dahlen SE, Lindgren JA, et al. Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science 1987, 237:1171-1176.
228. Serhan CN, Chiang N Novel endogenous small molecules as the checkpoint controllers in inflammation and resolution: entree for resoleomics. Rheum Dis Clin North Am 2004, 30:69-95.
229. Levy BD, Clish CB, Schmidt B, et al. Lipid mediator class switching during acute inflammation: signals in resolution. Nat Immunol 2001, 2:612-619.
230. Nathan C Points of control in inflammation. Nature 2002, 420:846-852.
231. Nathan C Nitric oxide as a secretory product of mammalian cells. FASEB J 1992, 6:3051-3064.
232. Chakravortty D, Hensel M Inducible nitric oxide synthase and control of intracellular bacterial pathogens. Microbes Infect 2003, 5:621-627.
233. Babior BM, Lambeth JD, Nauseef W The neutrophil NADPH oxidase. Arch Biochem Biophys 2002, 397:342-344.
234. Edwards SW, Watson F The cell biology of phagocytes. Immunol Today 1995, 16:508-510.
235. Mollinedo F, Borregaard N, Boxer LA Novel trends in neutrophil structure, function and development. Immunol Today 1999, 12:535-537.
236. Nagase H, Woessner JF Matrix Metalloproteinases. J Biol Chem 1999, 274:21491-21494.
237. Bode W Structural basis of matrix metalloproteinase function. Biochem Soc Symp 2003, 70:1-14.
238. Chikanza IC, Grossman AB Reciprocal interactions between the neuroendocrine and immune systems during inflammation. Rheum Dis Clin North Am 2000, 26:693-711.
239. Cutolo M, Bijlsma JW, Lahita RG, et al. Altered neuroendocrine immune (NEI) networks in rheumatology. Ann N Y Acad Sci 2002, 966:xiii-xviii.
240. Besson JM The neurobiology of pain. Lancet 1999, 353:1610-1615.
241. Niissalo S, Hukkanen M, Imai S, et al. Neuropeptides in experimental and degenerative arthritis. Ann N Y Acad Sci 2002, 966:384-399.
242. Vottero A, Chrousos GP Glucocorticoid receptor beta: view I. Trends Endocrinol Metab 1999, 10:333-338.
243. Chikanza IC Mechanisms of corticosteroid resistance in rheumatoid arthritis: a putative role for the corticosteroid receptor beta isoform. Ann N Y Acad Sci 2002, 966:39-48.
244. Vera-Lastra O, Jara LJ, Espinoza LR Prolactin and autoimmunity. Autoimmun Rev 2002, 1:360-364.
245. Calandra T, Roger T Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol 2003, 3:791-800.
246. De Benedetti F, Meazza C, Vivarelli M, et al. Functional and prognostic relevance of the -173 polymorphism of the macrophage migration inhibitory factor gene in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2003, 48:1398-1407.